$CBIH News

CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine

CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research

Years of Preparation. One Regulatory Approval. Commercial Launch Begins: CBIH Receives Texas License for Consumable Hemp Products

CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings

Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement

CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research

CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers

CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation

CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence

CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition

CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline

CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery

Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook

CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification

Cannabis Bioscience International Holdings (CBIH) Announces Partnership with Stephen Gould for Manufacturing and Distribution of Medical Products

CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing